WhaleCreep

BML Capital Management, LLC 13F holdings, Q3 2025

Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →

BML Capital Management, LLC disclosed 18 US equity positions worth $108.7m in its Q3 2025 13F filing. The largest position was ACRS at 24.9% of the reported book, followed by AVIR and AVU0. Against the Q2 2025 filing, it opened 6 new positions, added to 4 and reduced 2 among the top 18 holdings.

← Q2 2025 · Q4 2025 →

What did BML Capital Management, LLC own in Q3 2025? Top 18 positions

#StockSectorWeightValueSharesΔ sharesvs Q2 2025
1 ACRS ACLARIS THERAPEUTICS INC Healthcare 24.9%$27.1m14,250,000 0% held
2 AVIR ATEA PHARMACEUTICALS INC Healthcare 19.9%$21.7m7,473,963 -2% reduced
3 AVU0 ADVERUM BIOTECHNOLOGIES INC 12.7%$13.9m3,057,526 0% held
4 TIL INSTIL BIO INC 10.6%$11.5m645,600 21% added
5 ORMP ORAMED PHARMACEUTICALS INC 7.7%$8.4m3,167,231 3% added
6 PMVP PMV PHARMACEUTICALS INC 6.8%$7.4m5,292,000 6% added
7 ALMS ALUMIS INC 4.4%$4.8m1,210,415 0% held
8 LAVA THERAPEUTICS NV 2.8%$3.1m1,970,610 0% held
9 2KZ0 KEZAR LIFE SCIENCES INC 2.6%$2.8m720,787 13% added
10 CNTB CONNECT BIOPHARMA HLDGS LTD 1.8%$1.9m1,267,500 – new
11 IMA IMAGENEBIO INC 1.4%$1.5m182,509 – new
12 LONA ATHIRA PHARMA INC 1.2%$1.3m323,066 – new
13 ASTROTECH CORP 1.0%$1.1m220,410 0% held
14 TGT TARGET CORP Consumer Defensive 0.8%$897.0k10,000 – new
15 VTGN VISTAGEN THERAPEUTICS INC 0.5%$532.5k150,000 0% held
16 ARVN ARVINAS INC Healthcare 0.4%$426.0k50,000 – new
17 LSTA LISATA THERAPEUTICS INC 0.3%$287.8k109,841 -48% reduced
18 MURAL ONCOLOGY PUB LTD CO 0.1%$119.0k57,500 – new

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.